Monoamine oxidase and neurodegeneration: Mechanisms, inhibitors and natural compounds for therapeutic intervention

被引:11
作者
Banerjee, Chayan [1 ,2 ]
Tripathy, Debasmita [3 ]
Kumar, Deepak [4 ]
Chakraborty, Joy [1 ]
机构
[1] CSIR Indian Inst Chem Biol, Cell Biol & Physiol Div, Kolkata 700032, India
[2] Acad Sci & Innovat Res AcSIR, Ghaziabad 201002, India
[3] Netaji Nagar Coll Women, Dept Zool, Kolkata 700092, India
[4] CSIR Indian Inst Chem Biol, Organ & Med Chem Div, Kolkata 700032, India
关键词
Monoamine oxidase; Reactive oxygen species; Mitochondrial aberration; Neurological disorders; Parkinson's disease; Monoamine oxidase inhibitors; MAO-B INHIBITOR; HYDROGEN-PEROXIDE PRODUCTION; PARKINSONS-DISEASE PATIENTS; PLACEBO-CONTROLLED TRIAL; DELAYED-START TRIAL; POST-HOC ANALYSES; DOUBLE-BLIND; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; PARGYLINE HYDROCHLORIDE;
D O I
10.1016/j.neuint.2024.105831
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mammalian flavoenzyme Monoamine oxidase (MAO) resides on the outer mitochondrial membrane (OMM) and it is involved in the metabolism of different monoamine neurotransmitters in brain. During MAO mediated oxidative deamination of relevant substrates, H2O2 is released as a catalytic by-product, thus serving as a major source of reactive oxygen species (ROS). Under normal conditions, MAO mediated ROS is reported to propel the functioning of mitochondrial electron transport chain and phasic dopamine release. However, due to its localization onto mitochondria, sudden elevation in its enzymatic activity could directly impact the form and function of the organelle. For instance, in the case of Parkinson's disease (PD) patients who are on L-dopa therapy, the enzyme could be a concurrent source of extensive ROS production in the presence of uncontrolled substrate (dopamine) availability, thus further impacting the health of surviving neurons. It is worth mentioning that the expression of the enzyme in different brain compartments increases with age. Moreover, the involvement of MAO in the progression of neurological disorders such as PD, Alzheimer's disease and depression has been extensively studied in recent times. Although the usage of available synthetic MAO inhibitors has been instrumental in managing these conditions, the associated complications have raised significant concerns lately. Natural products have served as a major source of lead molecules in modern-day drug discovery; however, there is still no FDAapproved MAO inhibitor which is derived from natural sources. In this review, we have provided a comprehensive overview of MAO and how the enzyme system is involved in the pathogenesis of different age-associated neuropathologic conditions. We further discussed the applications and drawbacks of the long-term usage of presently available synthetic MAO inhibitors. Additionally, we have highlighted the prospect and worth of natural product derived molecules in addressing MAO associated complications.
引用
收藏
页数:19
相关论文
共 329 条
[81]  
FINBERG JPM, 1983, NEUROPHARMACOLOGY, V22, P441, DOI 10.1016/0028-3908(83)90194-6
[82]   TYRAMINE ANTAGONISTIC PROPERTIES OF AGN-1135, AN IRREVERSIBLE INHIBITOR OF MONOAMINE-OXIDASE TYPE-B [J].
FINBERG, JPM ;
TENNE, M ;
YOUDIM, MBH .
BRITISH JOURNAL OF PHARMACOLOGY, 1981, 73 (01) :65-74
[83]  
FINNERTY F A Jr, 1959, Georgetown Med Bull, V13, P80
[84]   Monoamine oxidase-A modulates apoptotic cell death induced by staurosporine in human neuroblastoma cells [J].
Fitzgerald, Julia C. ;
Ufer, Christoph ;
De Girolamo, Luigi A. ;
Kuhn, Hartmut ;
Billett, E. Ellen .
JOURNAL OF NEUROCHEMISTRY, 2007, 103 (06) :2189-2199
[85]   Monoamine oxidase-A knockdown in human neuroblastoma cells reveals protection against mitochondrial toxins [J].
Fitzgerald, Julia C. ;
Ugun-Klusek, Aslihan ;
Allen, George ;
De Girolamo, Luigi A. ;
Hargreaves, Iain ;
Ufer, Christoph ;
Abramov, Andrey Y. ;
Billett, E. Ellen .
FASEB JOURNAL, 2014, 28 (01) :218-229
[86]  
FORD RV, 1961, CURR THER RES CLIN E, V3, P378
[87]   TITRATION OF HUMAN-BRAIN MONOAMINE OXIDASE-A AND OXIDASE-B BY CLORGYLINE AND L-DEPRENIL [J].
FOWLER, CJ ;
ORELAND, L ;
MARCUSSON, J ;
WINBLAD, B .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1980, 311 (03) :263-272
[88]   THE EFFECT OF AGE ON THE ACTIVITY AND MOLECULAR-PROPERTIES OF HUMAN-BRAIN MONOAMINE-OXIDASE [J].
FOWLER, CJ ;
WIBERG, A ;
ORELAND, L ;
MARCUSSON, J ;
WINBLAD, B .
JOURNAL OF NEURAL TRANSMISSION, 1980, 49 (1-2) :1-20
[89]   Evidence that Formulations of the Selective MAO-B Inhibitor, Selegiline, which Bypass First-Pass Metabolism, also Inhibit MAO-A in the Human Brain [J].
Fowler, Joanna S. ;
Logan, Jean ;
Volkow, Nora D. ;
Shumay, Elena ;
McCall-Perez, Fred ;
Jayne, Millard ;
Wang, Gene-Jack ;
Alexoff, David L. ;
Apelskog-Torees, Karen ;
Hubbard, Barbara ;
Carter, Pauline ;
King, Payton ;
Fahn, Stanley ;
Gilmor, Michelle ;
Telang, Frank ;
Shea, Colleen ;
Xu, Youwen ;
Muench, Lisa .
NEUROPSYCHOPHARMACOLOGY, 2015, 40 (03) :650-657
[90]   SELECTIVE MONOAMINE-OXIDASE INHIBITOR DRUGS AS AIDS IN EVALUATING ROLE OF TYPE-A AND B ENZYMES [J].
FUENTES, JA ;
NEFF, NH .
NEUROPHARMACOLOGY, 1975, 14 (11) :819-825